

Amendment Tool

v1.8 30 April 2025

For office use

QC: No

Section 1: Project information

Short project title*:	Indigo		
IRAS project ID* (or REC reference if no IRAS project ID is available):	324034		
Sponsor amendment reference number*:	NSA_10		
Sponsor amendment date* (enter as DD/MM/YY):	10 November 2025		
Briefly summarise in lay language the main changes proposed in this amendment. Explain the purpose of the changes and their significance for the study. If the amendment significantly alters the research design or methodology, or could otherwise affect the scientific value of the study, supporting scientific information should be given (or enclosed separately). Indicate whether or not additional scientific critique has been obtained (note: this field will adapt to the amount of text entered)*:	<p>We wish to extend our study by 24 months (updated end date: 01st December 2028) in order to focus recruitment on under-represented groups (e.g., patients from minorities, young patients, rare cancer types). We shall work with primary care sites and secondary care trusts that cover deprived areas to target these patients groups. These sites are already running the trial and have been added as sites in previous amendments.</p> <p>The documents affected by these changes are listed below:</p> <ul style="list-style-type: none"> - Indigo - protocol - 2025.10.31_v1.7.docx - Indigo - Differences between posters - 2025.11.12 - v0.1.pptx - Indigo - Poster 1 - Template - 2025.10.31_v0.2.2025.png - Indigo - Poster 1 - Template - 2025.10.31_v0.2.2026.png - Indigo - Poster 2 - Template - 2025.10.31_v0.2.2025.png - Indigo - Poster 2 - Template - 2025.10.31_v0.2.2026.png - Indigo Community - Adverts (overall) - 2025.10.31 - v1.6.docx 		
Project type (select):	Specific study		
	Research tissue bank		
	Research database		
Has the study been reviewed by a UKECA-recognised Research Ethics Committee (REC) prior to this amendment?:	Yes	No	
What type of UKECA-recognised Research Ethics Committee (REC) review is applicable? (select):	NHS/HSC REC		
	Ministry of Defence (MoDREC)		
Is all or part of this amendment being resubmitted to the Research Ethics Committee (REC) as a modified amendment (i.e. a substantial amendment previously given an unfavourable opinion)?	Yes	No	
Where is the NHS/HSC Research Ethics Committee (REC) that reviewed the study based?:	England	Wales	Scotland
	Yes	No	No
Was the study a clinical trial of an investigational medicinal product (CTIMP) OR does the amendment make it one?:	Yes	No	
Was the study a clinical investigation or other study of a medical device OR does the amendment make it one?:	Yes	No	
Was the study a performance evaluation study of an In Vitro Diagnostic (IVD) medical device^ (including as a companion diagnostic in a clinical trial of an investigational medicinal product)?:	Yes	No	
Does the amendment make the study a performance evaluation study of an In Vitro Diagnostic (IVD) medical device^ (including as a companion diagnostic in a clinical trial of an investigational medicinal product)?:	Yes	No	
^ IVD medical devices are tests used on biological samples, such as tissues, blood or urine, to determine the status of a person's health. This may be a reagent, reagent product, calibrator, control material, kit, instrument, apparatus, equipment or system, whether used alone or in combination			
Did the study involve the administration of radioactive substances, therefore requiring ARSAC review, OR does the amendment introduce this?:	Yes	No	
Did the study involve the use of research exposures to ionising radiation (not involving the administration of radioactive substances) OR does the amendment introduce this?:	Yes	No	
Did the study involve adults lacking capacity OR does the amendment introduce this?:	Yes	No	
Does the study involve access to confidential patient information outside the direct care team without consent OR does the amendment introduce this?: (e.g. the study relies upon section 251 support in England and Wales, or equivalent in Scotland to set aside the common law duty of confidentiality)	Yes	No	

Does the study involve prisoners or young offenders who are in custody or supervised by the probation service OR does the amendment introduce this?:	Yes		No	
Does the study involve children OR does the amendment introduce this?:	Yes		No	
Did the study involve NHS/HSC organisations prior to this amendment?:	Yes		No	
Did the study involve non-NHS/HSC organisations OR does the amendment introduce them?:	Yes		No	
	England	Wales	Scotland	Northern Ireland
Lead nation for the study:	Yes	No	No	No
Which nations had participating NHS/HSC organisations prior to this amendment?	Yes	No	No	No
Which nations will have participating NHS/HSC organisations after this amendment?	Yes	No	No	No
Was this a "single site, self sponsored" study in England or Wales prior to this amendment?	Yes		No	

Section 2: Summary of change(s)

Please note: Each change being made as part of the amendment must be entered separately. For example, if an amendment to a clinical trial of an investigational medicinal product (CTIMP) involves an update to the Investigator's Brochure (IB), affecting the Reference Safety Information (RSI) and so the information documents to be given to participants, these should be entered into the Amendment Tool as three separate changes. A list of all possible changes is available on the "Glossary of Amendment Options" tab. To add another change, click the "Add another change" box.

Change 1				
Area of change (select)*:	Study Design			
Specific change (select - only available when area of change is selected first)*:	Extension to study duration that will have additional resource implications for participating organisations - Please specify in the free text below			
Further information: explain what the change is, why the change is being made and any possible impact on study participants/carers. In particular, please describe the additional resource arrangements that participating organisations will need to have in place to implement this change (free text - note that this field will adapt to the amount of text entered)*:	Following our preliminary analyses of patients recruited so far, we would like to extend the study duration to focus on recruiting young patients, patients diagnosed with rare cancer and patients from minorities (e.g., patients of black ethnicity). The new study end date is therefore 1st December 2028.			
Applicability:	England	Wales	Scotland	Northern Ireland
Where are the participating NHS/HSC organisations located that will be affected by this change?*	Yes	No	No	No
Will all participating NHS/HSC organisations be affected by this change, or only some? (please note that this answer may affect the categorisation for the change):	All		Some	
Remove all changes below				

Change 2				
Area of change (select)*:	Study Documents			
Specific change (select - only available when area of change is selected first)*:	Other minor change to study documents (e.g. information sheets, consent forms, questionnaires, letters) that can be implemented within existing resource in place at participating organisations - Please specify in the free text below			
Further information: explain what the change is, why the change is being made and any possible impact on study participants/carers. In particular, please describe why this change can be implemented within the existing resource in place at the participating organisations (free text - note that this field will adapt to the amount of text entered)*	<p>Following the first change of this amendment (i.e., extension of the study duration), the year when patients finished their initial treatment has been updated to reflect the extension to the study duration. Only the year has changed.</p> <p>The documents affected by this change are listed below:</p> <ul style="list-style-type: none"> - Indigo – Differences between posters - 2025.11.12 - v0.1.pptx - Indigo - Poster 1 - Template - 2025.10.31_v0.2.2025.png - Indigo - Poster 1 - Template - 2025.10.31_v0.2.2026.png - Indigo - Poster 2 - Template - 2025.10.31_v0.2.2025.png - Indigo - Poster 2 - Template - 2025.10.31_v0.2.2026.png - Indigo Community - Adverts (overall) - 2025.10.31 - v1.6.docx 			
Applicability:	England	Wales	Scotland	Northern Ireland
Where are the participating NHS/HSC organisations located that will be affected by this change?*	Yes	No	No	No
Will all participating NHS/HSC organisations be affected by this change, or only some? (please note that this answer may affect the categorisation for the change):	All		Some	

Remove all changes below

Change 3				
Area of change (select)*:	Study Documents			
Specific change (select - only available when area of change is selected first)*:	Protocol - Non-substantial changes (e.g. not affecting safety or the scientific value of the trial)			
Further information: explain what the change is, why the change is being made and any possible impact on study participants/carers (free text - note that this field will adapt to the amount of text entered):	Following Change 1, the protocol reflects this change. The documents affected by this change are listed below: - Indigo - protocol - 2025.10.31_v1.7.docx			
Applicability:	England	Wales	Scotland	Northern Ireland
Where are the participating NHS/HSC organisations located that will be affected by this change?*	Yes	No	No	No
Will all participating NHS/HSC organisations be affected by this change, or only some? (please note that this answer may affect the categorisation for the change):	All		Some	
Add another change				

Section 3: Declaration(s) and lock for submission

Declaration by the Sponsor or authorised delegate

- I confirm that the Sponsor takes responsibility for the completed amendment tool
- I confirm that I have been formally authorised by the Sponsor to complete the amendment tool on their behalf

Name [first name and surname]*: Eleanor Izzard

Email address*: e.izzard@imperial.ac.uk

Lock for submission

Please note: This button will only become available when all mandatory (*) fields have been completed. When the button is available, clicking it will generate a locked PDF copy of the completed amendment tool which must be included in the amendment submission. Please ensure that the amendment tool is completed correctly before locking it for submission.

Lock for submission

After locking the tool, [proceed to submit the amendment online](#). The "Submission Guidance" tab provides further information about the next steps for the amendment.

Section 4: Review bodies for the amendment

Please note: This section is for **information only**. Details in this section will complete automatically based on the options selected in Sections 1 and 2.

	Review bodies																		Category:
	UK wide:						England and Wales:				Scotland:				Northern Ireland:				
	REC	Competent Authority MHRA - Medicines	Competent Authority MHRA - Devices	ARSAC	Radiation Assurance	UKSW Governance	REC (MCA)	CAG	HMPPS	HRA and HCRW Approval	REC (AWIA)	PBPP	SPS (RAEC)	National coordinating function	HSC REC	HSC Data Guardians	Prisons	National coordinating function	
Change 1:						(Y)				(Y)									A
Change 2:						(Y)				(Y)									C
Change 3:						(Y)				(Y)									A
Overall reviews for the amendment:																			
Full review:						N				N									

Notification only:						Y					Y								
Overall amendment type:	Non-substantial, no study-wide review required																		
Overall Category:	A																		